*Read Disclaimer Sponsored Content | Unsubscribe
Hello!
Following our alert this morning, NNVC opened at 1.44.
So far, that is near the 1.47 high of the day, so no tangible gains yet.
Here are a couple of the things to keep in mind for upside potential.
Continue to watch for it to hold above its 200 day moving average of 1.39, that's the first sign.
A rally and close above the 50 day moving average of 1.52 could result in increased upside.
In addition, NNVC has a RSI of 48 – showing upside potential.
A close near the high and rally above the 50 day moving average could signal the beginning of the renewed breakout.
In July, the company traded as high as 1.79, +24% from today's open.
Here are NNVC's two recent announcements:
Today, they are presenting "at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025".
As the company mentioned in this press release from last week:
"Anil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline and Platform Technologies available for licensing."
In addition:
"Dr. Diwan has several pre-scheduled meetings in the partnering sessions and will also be available for meetings during the Congress on September 16th and 17th outside his busy schedule."
The "LSX World Congress-USA is where innovators, investors and senior life science dealmakers in the LSX community connect, learn and partner."
"The Congress gathers leaders from the US biotech, medtech, and pharmatech sectors to network, showcase innovations, and explore partnership opportunities."
"It offers a unique platform for CEOs, investors, and pharma executives to engage in meaningful discussions and collaborative sessions, shaping the future of healthcare technology."
"Empowering innovation, accelerating investment and facilitating partnering to shape the future of healthcare is the objective of LSX World Congress."
As the company explained in August:
"A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials"
Importantly, from this press release:
"NV-387 is the only antiviral drug that has been uniquely found to be effective in the treatment of lethal lung viral infections caused by all of these viruses in animal model studies that are predictive of human clinical effectiveness."
"This clearly demonstrates the unmet medical need for NV-387, a broad-spectrum antiviral that the viruses cannot escape even as new variants are created. In contrast, antibodies and vaccines readily fail with new variants arising, as is now well known."
"NV-387 treatment has been found to reduce the level of IL-6 in lethal viral infections causing lung diseases in animal models. Excellent protection of lungs was found to occur in NV-387-treated animals but not in ribavirin treated animals in a lethal RSV infection study. Strong protection of lungs was found to occur in NV-387-treated animals in a lethal lung-infection of Influenza A/H3N2 study."
"In this Influenza study, the approved drugs Tamiflu (oseltamivir), Rapivab (peramivib), and Xofluza (baloxavir) failed to protect the lungs of animals to any appreciable extent, indicating the superiority and clinical viability of NV-387."
"The Company further investigated the extra-ordinary effect of NV-387 on protection of lungs in lethal viral infections. Reduction in inflammatory cytokines, particularly IL-6, was found to occur to an appreciable extent in NV-387 treated animals."
As more investors discover this company, they could notice what we believe to be an overlooked opportunity.
Sources: PR1, PR2, PR3, PR4, PR5, PR6, PR7, PR8, Website, Chart
Happy Trading!
AwesomeStocks
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.